These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27387766)

  • 21. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.
    Rodgers GM; Gilreath JA
    Acta Haematol; 2019; 142(1):13-20. PubMed ID: 30970366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE
    Blood; 2008 Jan; 111(1):25-41. PubMed ID: 17954703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.
    Zuccarini A; Cicognini D; Tancredi R; Ferrari A; Rizzo G; Lasagna A; Caccialanza R; Cavanna L; Orlandi E; Biasini C; Molinaro P; Garigliano D; Costantino A; Moroni M; Perrone L; Alessio NL; Rovati B; Ferretti VV; Klersy C; Pedrazzoli P
    Support Care Cancer; 2022 Sep; 30(9):7645-7653. PubMed ID: 35678882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.
    Sanz Ortiz J
    Clin Transl Oncol; 2008 Aug; 10(8):486-92. PubMed ID: 18667379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
    Robles NR
    Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.
    Chen L; Jiang H; Gao W; Tu Y; Zhou Y; Li X; Zhu Z; Jiang Q; Zhan H; Yu J; Fu C; Gao Y
    BMJ Open; 2016 Oct; 6(10):e012231. PubMed ID: 27855097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients.
    Steinmetz T; Kuhr K; Totzke U; Hellmich M; Heinz M; Neise M; Mittermüller J; Tessen HW; Reiser M; Severin K; Schmitz S
    Clin Chem Lab Med; 2013 Sep; 51(9):1849-57. PubMed ID: 23729581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacist collaborative practice agreement for the management of anemia in malignant disease with erythropoiesis-stimulating agents.
    Weil E; Oxencis C
    Support Care Cancer; 2015 Aug; 23(8):2507-13. PubMed ID: 25971214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.
    Ludwig H; Aapro M; Bokemeyer C; Glaspy J; Hedenus M; Littlewood TJ; Österborg A; Rzychon B; Mitchell D; Beguin Y
    Support Care Cancer; 2014 Aug; 22(8):2197-206. PubMed ID: 24659244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
    Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
    Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of erythropoiesis-stimulating agents in the intensive care unit.
    Piagnerelli M; Vincent JL
    Crit Care Clin; 2012 Jul; 28(3):345-62, v. PubMed ID: 22713610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.